6533b859fe1ef96bd12b6e38

RESEARCH PRODUCT

Comparison of the value of PCNA and Ki-67 as markers of cell proliferation in ameloblastic tumors

Adalberto Mosqueda-taylorGuillermo Sánchez-acuñaAna-dolores Mori-estevezRonell Bologna-molinaNelly Molina-frechero

subject

Pathologymedicine.medical_specialtyCARCINOMADesmoplastic ameloblastomagovernment.form_of_governmentOdontologíaAmeloblastomaANTIGENO NUCLEAR DE CELULA EN PROLIFERACIONChemical markerCell proliferation markersstomatognathic systemProliferating Cell Nuclear AntigenProliferation ratemedicinePCNAHumansGeneral DentistryCell ProliferationRetrospective StudiesAmeloblastomasOral Medicine and PathologybiologyCell growthbusiness.industry:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludANTIGENO Ki-67Proliferating cell nuclear antigenAmeloblastic carcinomaKi-67 AntigenAMELOBLASTOMAOtorhinolaryngologyKi-67UNESCO::CIENCIAS MÉDICASbiology.proteingovernmentKi-67ImmunohistochemistryResearch-ArticleMouth NeoplasmsSurgerybusinessBiomarkersAmeloblastic carcinoma

description

Objectives: The aim of this study was to compare among PCNAand Ki-67 as the most reliable immunohisto chemical marker for evaluating cell proliferation in ameloblastic tumors. Study Design: Observational, retrospective, and descriptive study of a large series of ameloblastic tumors, com- D esign: Observational, retrospective, and descriptive study of a large series of ameloblastic tumors, com- esign: Observational, retrospective, and descriptive study of a large series of ameloblastic tumors, com posed of 161 ameloblastomas and four ameloblastic carcinomas, to determine and compare PCNA and Ki-67 expression using immunohistochemistry techniques. Results: When analyzing Ki-67 positivity, the desmoplastic ameloblastoma demonstrated a significantly lower proliferation rate (1.9%) compared with the solid/multicystic and unicystic ameloblastomas and ameloblastic car cinomas (p<0.05), whereas the ameloblastic carcinomas displayed a significantly higher rate compared with all of the other ameloblastomas (48.7%) (p<0.05). When analyzing cell proliferation with PCNA, we found significant differences only between the ameloblastic carcinomas (93.3%) and the desmoplastic ameloblastomas (p<0.05). When differences between the immunopositivity for PCNA and Ki-67 were compared, the percentages were higher for PCNA in all types of ameloblastomas and ameloblastic carcinomas. In all cases, the percentages were greater than 80%, whereas the immunopositivity for Ki-67 was significantly lower; for example, the ameloblastic carcinoma expressed the highest positivity and only reached 48.7%, compared to 93.3% when we used PCNA. Conclusions: In the present study, when we used the proliferation cell marker Ki-67, the percentages of positiv ity were more specific and varied among the different types of ameloblastomas, suggesting that Ki-67 is a more specific marker for the proliferation of ameloblastic tumor cells

yearjournalcountryeditionlanguage
2012-12-01
http://hdl.handle.net/10550/35584